EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers

Isabel Moscoso iD, Moisés Rodríguez-Mañero, María Cebro-Márquez iD, Marta E Vilar-Sánchez, Valentina Serrano-Cruz iD, Iria Vidal-Abeijón, María Amparo Martínez-Monzonís, Pilar Mazón-Ramos, Milagros Pedreira, José Ramón González-Juanatey iD, Ricardo Lage

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252211910 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Isabel Moscoso und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Group, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Instituto de Investigación Sanitaria de Santiago de Compost…. Hauptthemen laut MEDLINE: MicroRNAs, Cardiotoxicity, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sociedad Española de Cardiología (SEC), Xunta de Galicia, Instituto de Salud Carlos III (ISCIII) CIBERCV.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiotoxicity (CDTX) is a critical side effect of many cancer therapies, leading to increased morbidity and mortality if not addressed. Early detection of CDTX is essential, and while echocardiographic measures like global longitudinal strain offer promise in identifying early myocardial dysfunction, the search for reliable biomarkers continues. MicroRNAs (miRNAs) are emerging as important non-coding RNA molecules that regulate gene expression post-transcriptionally, influencing key biological processes such as the cell cycle, apoptosis, and stress responses. In cardiovascular diseases, miRNAs have demonstrated potential as biomarkers due to their stability in circulation and specific expression patterns that reflect pathological changes. Certain miRNAs have been linked to CDTX and hold promise for early detection, prognosis, and therapeutic targeting. These miRNAs not only assist in identifying early cardiac injury, but also offer opportunities for personalized interventions by modulating their expression to influence disease progression. As research advances, integrating miRNA profiling with traditional diagnostic methods could enhance the management of CDTX in cancer patients, paving the way for improved patient outcomes and more tailored therapeutic strategies. Further clinical studies are essential to validate the clinical utility of miRNAs in managing CDTX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCardiotoxicityNeoplasmsHumansBiomarkersAntineoplastic AgentsAnimals

Stichwörter der Autor:innen

biomarkerscardiotoxicitymicroRNAs

Substanzen

MicroRNAsBiomarkersAntineoplastic Agents

Autor:innen und Institutionen

  • Cardiology Group, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), University of Santiago de Compostela, 15782 Santiago de Co…
  • Department of Cardiology and Coronary Unit, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain.
  • Department of Biochemistry and Molecular Biology, Faculty of Medicine, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.

ORCID-Profile: Isabel Moscoso, María Cebro-Márquez, Valentina Serrano-Cruz, José Ramón González-Juanatey

Förderung

  • Sociedad Española de Cardiología (SEC)
  • Xunta de Galicia
  • Instituto de Salud Carlos III (ISCIII) CIBERCV
  • Xunta de Galicia: Programa de Consolidación de Unidades de Investigación Competitivas do SUG
  • Centro Singular de Investigación de Galicia acreditación 2019–2022
  • European Union European Regional Development Fund (ERDF)

Zitieren

APA

Moscoso, I., Rodríguez-Mañero, M., Cebro-Márquez, M., Vilar-Sánchez, M. E., Serrano-Cruz, V., Vidal-Abeijón, I., Martínez-Monzonís, M. A., Mazón-Ramos, P., Pedreira, M., González-Juanatey, J. R., & Lage, R. (2024). Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252211910

Vancouver

Moscoso I, Rodríguez-Mañero M, Cebro-Márquez M, Vilar-Sánchez ME, Serrano-Cruz V, Vidal-Abeijón I, et al. Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252211910

BibTeX
@article{Moscoso2024,
  author = {Moscoso, Isabel and Rodríguez-Mañero, Moisés and Cebro-Márquez, María and Vilar-Sánchez, Marta E and Serrano-Cruz, Valentina and Vidal-Abeijón, Iria and Martínez-Monzonís, María Amparo and Mazón-Ramos, Pilar and Pedreira, Milagros and González-Juanatey, José Ramón and Lage, Ricardo},
  title = {Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252211910}
}
Kostenlos starten →